Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 4c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.17), $0.04 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $120 thousand versus the consensus estimate of $125 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Infosys expands multi-year IT managed services deal with GlobalFoundries